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OBJECTIVE — Admission hyperglycemia has been associated with worse outcomes in isch-
emic stroke. We hypothesized that hyperglycemia (glucose 8.0 mmol/l) in the hyperacute
phase would be independently associated with increased mortality, symptomatic intracerebral
hemorrhage (SICH), and poor functional status at 90 days in stroke patients treated with intra-
venous tissue plasminogen activator (IV-tPA).
RESEARCH DESIGN AND METHODS — Using data from the prospective, multi-
center Canadian Alteplase for Stroke Effectiveness Study (CASES), the association between
admission glucose 8.0 mmol/l and mortality, SICH, and poor functional status at 90 days
(modiﬁed Rankin Scale 1) was examined. Similar analyses examining glucose as a continuous
measure were conducted.
RESULTS — Of 1,098 patients, 296 (27%) had admission hyperglycemia, including 18% of
those without diabetes and 70% of those with diabetes. After multivariable logistic regression,
admission hyperglycemia was found to be independently associated with increased risk of death
(adjustedriskratio1.5[95%CI1.2–1.9]),SICH(1.69[0.95–3.00]),andadecreasedprobability
of a favorable outcome at 90 days (0.7 [0.5–0.9]). An incremental risk of death and SICH and
unfavorable90-dayoutcomeswasobservedwithincreasingadmissionglucose.Thisobservation
held true for patients with and without diabetes.
CONCLUSIONS — In this cohort of IV-tPA–treated stroke patients, admission hyperglyce-
miawasindependentlyassociatedwithincreasedriskofdeath,SICH,andpoorfunctionalstatus
at 90 days. Treatment trials continue to be urgently needed to determine whether this is a
modiﬁable risk factor for poor outcome.
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A
dmission hyperglycemia has been
associated with a worse functional
outcome after ischemic stroke (1–
3). Poor functional outcomes and in-
creased mortality have been described in
nonthrombolyzed cohorts, and increased
rates of intracerebral hemorrhage (ICH)
have been found in the few studies in
which patients treated with intravenous
tissue plasminogen activator (IV-tPA)
were studied exclusively (4–6). Baseline
hyperglycemia is found more commonly
inpatientswithpreexistingdiabetesbutis
also present in a signiﬁcant proportion of
nondiabetic patients (1). A causal rela-
tionship between elevated glucose and
worse outcomes has not yet been proven,
but current guidelines suggest that exces-
sive hyperglycemia be treated in acute
stroke patients (7). Trials of insulin ther-
apytotreathyperglycemiainacutestroke
are ongoing (Glucose Regulation in Acute
Stroke Patients [GRASP] trial), and two
smaller studies showing equivocal results
have been published (8,9).
The bulk of previous studies explor-
ing the role of hyperglycemia in stroke
haveincludedonlynonthrombolyzedpa-
tients. Glucose values were measured be-
yondthehyperacute(3h)phase,andin
several of these studies, ischemic and
hemorrhagic strokes were pooled in the
analyses (1–3,10). The few studies of ad-
mission glucose in tPA-treated ischemic
stroke patients have all been relatively
small (the largest included 748 patients)
(4–6,11–15); some were retrospective
(5,14), examined only ICH (5) or short-
term(30days)outcomes(12,14,15),or
included patients treated with IV-tPA be-
yond 3 h (6,14) or with intra-arterial tPA
(11).Wesoughttodeterminewhether,in
a large national cohort of stroke patients
treated with standard protocol IV-tPA, el-
evated admission glucose was associated
with worse outcomes, particularly dis-
ability, death, and symptomatic ICH
(SICH).
RESEARCH DESIGN AND
METHODS— Data prospectively col-
lected in the Canadian Alteplase for
Stroke Effectiveness Study (CASES) were
analyzed (16). This was a national pro-
spective cohort study that led to the full
approval of IV-tPA for acute ischemic
stroke in Canada. Sixty sites across the
country participated over a period of 2.5
yearsand,whererelevant,eachcenterob-
tained institutional ethics approval for
data collection. If patients were incapaci-
tated by their stroke, next of kin provided
informedconsent.Patientsweretreatedat
the discretion of the site neurologist ac-
cording to Canadian guidelines for intra-
venous thrombolytic treatment in acute
stroke (17).
Baseline demographic data were ob-
tained as were pretreatment basic blood
tests and data regarding timing of drug
administration and stroke subtype as de-
terminedbythesiteinvestigatorusingthe
Oxfordshire Community Stroke Project
classiﬁcation. Baseline glucose was deter-
mined before IV-tPA administration, ei-
ther by laboratory blood testing or from
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used was determined by the site’s own
usual practice and was not speciﬁcally re-
corded. The severity of the baseline neu-
rological deﬁcit was assessed with the
National Institutes of Health Stroke Scale
(NIHSS)beforetreatment.TheNIHSSisa
validated 11-domain systematic assess-
ment tool that provides a quantitative
measure of stroke-related neurologic def-
icit, such that a higher score corresponds
to a more severe deﬁcit (mild 0–15, se-
vere 15, and maximum 42). The out-
come was measured using the 7-point
modiﬁed Rankin Scale (mRS) at 90 days
by clinicians who were not necessarily
blinded to patients’ baseline glucose val-
ues. A favorable outcome was deﬁned as
an mRS of 0–1.
All patients underwent a follow-up
head computed tomography (CT) scan at
24–48 h. Baseline and follow-up CT
scans were centrally reviewed by a stroke
neurologist and neuroradiologist blinded
to clinical information, and the Alberta
Stroke Program Early CT Score (ASPECTS)
was applied. ASPECTS is a validated 10-
point score assessing the extent of infarc-
tion in strokes of the middle cerebral
artery using noncontrast CT. A lower
score suggests a more extensive area of
infarction (minimum score 0) (18). SICH
was deﬁned as any hemorrhage docu-
mented on a follow-up CT scan that was
associated with a decline in neurological
status within the ﬁrst 24 h after thrombo-
lytictreatmentasjudgedbythesiteinves-
tigator, who was not blinded to clinical
information.AsymptomaticICHinvolved
hemorrhageonafollow-upCTscanwith-
out associated clinical deterioration.
Thedeﬁnitionofadmissionhypergly-
cemia was prespeciﬁed to be serum glu-
cose 8.0 mmol/l in accordance with
other studies (10,13,19). As a primary
analysis, patients were dichotomized into
those with admission hyperglycemia and
those without hyperglycemia and com-
pared with regard to baseline characteris-
tics, rate of SICH, functional outcome at
90 days, and death. A secondary analysis
examined the association of these out-
comes with admission glucose as a con-
tinuous measure.
Statistical analysis
Standard descriptive statistics were used
to report the data. Fisher’s exact test and
Student’s t test were used to compare the
twogroups.Bothbinomialregressionand
logistic regression were used to develop
models for the three outcomes of interest
depending upon use. The large sample
size provided sufﬁcient power to perform
multivariable analysis. For graphical de-
scriptions, multivariable logistic regres-
sionwasusedtoplotadjustedcurves.For
tabular description of risk ratios (RRs),
multivariable binomial regression was
usedtoidentifypredictorsofoutcomeus-
ing a log-link function. The ﬁnal models
were all parsimonious models, meaning
that variables that were not signiﬁcant
at P  0.05 or variables that showed no
evidence of confounding were elimi-
nated from the ﬁnal models. Models
were developed by backwards stepwise
elimination beginning with the vari-
ables listed in Table 1. Analyses were
conducted using STATA 8.2 (Stata-
Corp, College Station, TX).
RESULTS
Baseline characteristics
Of 1,135 patients enrolled in CASES,
1,098 had adequate admission glucose
data for inclusion in the current study. Of
these patients, median age was 73 years,
45% were women, 96% had an anterior
circulation stroke, and 16% had a known
prior history of diabetes. A glucose value
of 8.0 mmol/l corresponded to the 75th
percentile and, overall, 296 (27%) pa-
tients had admission hyperglycemia. Hy-
perglycemia was present in 70% of those
with diabetes and 18% of those without
diabetes. Hyperglycemic patients were
older; were more likely to be non-
Caucasian; were more likely to have atrial
ﬁbrillation, hypertension, congestive
heart failure, coronary artery disease, and
knowndiabetes;andwerelesslikelytobe
current smokers. The greater prevalence
of comorbid illness in the hyperglycemic
group is probably explained by older age
and the higher proportion of diabetes.
There were no differences in sex, stroke
subtype, or baseline stroke severity be-
tween groups (Table 1). No relationship
was observed between baseline serum
glucose and baseline NIHSS score.








Age (years) 69.7  13.6 71.6  12.0 0.03
Sex (female) 370 (46.4) 125 (42.7) 0.3
Caucasian 699 (92.6) 232 (86.2) 0.003
Vascular risk factors
Hypertension 369 (48.1) 156 (57.4) 0.009
Diabetes 50 (6.5) 116 (42.6) 0.001
Atrial ﬁbrillation 160 (20.9) 74 (27.2) 0.035
Dyslipidemia 141 (18.4) 59 (21.7) 0.25
Current cigarette use 130 (16.9) 29 (10.7) 0.014
Ischemic heart disease 165 (21.5) 89 (32.7) 0.001
Valvular heart disease 30 (3.9) 9 (3.3) 0.85
Congestive heart failure 41 (5.3) 31 (11.4) 0.001
Prior stroke/transient ischemic attack 170 (22.2) 72 (26.5) 0.16
Pretreatment systolic blood pressure
(mmHg) 151  21.6 153  21.8 0.18
Pretreatment ASPECTS 8 8 0.64
Baseline NIHSS 14 15 0.14
Protocol violations, all causes 113 (14.1) 39 (13.2) 0.77
Onset-to-treatment time (min) 150  37.2 150  38.9 0.92
Oxfordshire Community Stroke Project
stroke subtype 0.8
Total anterior circulation 198 (26.4) 82 (31.1)
Partial anterior circulation 481 (64.1) 155 (58.7)
Posterior circulation 22 (2.9) 13 (4.9)
Lacunar 49 (6.5) 14 (5.3)
Data are means  SD, median, or n (%). Not all percentages are calculated from the total number of patients
because certain clinical variables were not available for all patients.
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Rates of ICH, 90-day outcomes, and mor-
tality are shown in Table 2. A total of 49
(4.5%) patients had SICH. Among hyper-
glycemic patients, this proportion was
6.8% compared with 3.6% for nonhyper-
glycemic patients (P  0.03), resulting in
an unadjusted RR of 1.87 (95% CI 1.07–
3.25) for SICH in patients with baseline
glucose 8.0 mmol/l (Table 2). Multiva-
riable regression attenuated this relation-
ship somewhat, yielding an adjusted RR
of 1.69 (95% CI 0.95–3.00).
Clinical outcomes at 90 days, unad-
justed for confounders, are shown in Fig.
1. Only 80 (27.7%) hyperglycemic pa-
tients experienced a favorable functional
outcome (mRS 0–1) compared with 316
(40%) nonhyperglycemic patients (P 
0.0002). The proportion of patients who
were dead at the 3 month follow-up was
also signiﬁcantly higher among patients
with admission glucose 8.0 mmol/l
(30.8 vs. 18.7%, P  0.0001). Unad-
justed risk ratios for favorable outcome
and death among hyperglycemic patients
were 0.69 (95% CI 0.56–0.85) and 1.64
(1.31–2.06), respectively.
After multivariable regression, ad-
justed risk ratios were 0.7 (95% CI 0.5–
0.9) for favorable outcome and 1.5 (1.2–
1.9) for death. Multivariable analysis
showed that independent predictors of
90-day outcome and death were age,
baseline NIHSS, baseline ASPECTS, and
admission glucose. Each of these had a
comparable magnitude of association
withoutcome.Whendichotomizedasage
80 years, baseline NIHSS 15, and AS-
PECTS 7, unadjusted RRs for favorable
functional outcome were 0.64 (95% CI
0.52–0.80), 0.40 (0.32–0.48), and 1.53
(1.26–1.86), respectively. The negative
association between admission glucose
and functional outcome and death per-
sistedevenafterexclusionofpatientswith
SICH, a known independent predictor of
death and disability after thrombolysis
(4,20). These relationships were not dif-
ferent for patients with and without dia-
betes (no evidence of an interaction
effect).
Effect of stroke subtype and severity
No heterogeneity was found with regard
to the association between baseline hy-
perglycemia and a favorable clinical out-
come when analyzed by Oxfordshire
Community Stroke Project stroke sub-
type (
2 test, P  0.80) or when mild
strokes (NIHSS 5) and moderate-to-
severe strokes were compared (
2 test,
P  0.29), suggesting a deleterious effect
of hyperglycemia on outcome regardless
of stroke subtype or severity.
Admission glucose as a continuous
measure
Withglucoseasacontinuousvariable,the
predicted probability of SICH adjusted
for age, atrial ﬁbrillation, onset-to-
treatment time, and sex was calculated
and represented as a fractional polyno-
mial estimate of best ﬁt (Fig. 2A). An in-
creasing probability of SICH was seen
withincreasingadmissionglucosevalues.
Similarly, the predicted probability of
death at 90 days according to admission
glucose,adjustedforage,baselineNIHSS,
ASPECTS, onset-to-treatment time, and
sex was calculated and represented using
a linear least-squares line of best ﬁt (Fig.
2B).Anincreasingriskofdeathwasfound
with increasing baseline glucose. Finally,
the predicted probability of a favorable
outcome at 90 days, adjusted for age,
baseline NIHSS, ASPECTS, congestive
heart failure, atrial ﬁbrillation, and diabe-
tes was determined, yielding an inverse
relationship between admission glucose
Figure 1— Patient outcome at the 90-day follow-up by baseline glucose (unadjusted for other
predictors of outcome). mRS 0–1, excellent outcome; mRS 2–3, moderate disability; mRS 4–5,
severe disability; and mRS 6, dead.
Table 2—Outcome at 90 days and SICH in hyperglycemic (baseline glucose >8 mmol/l) and nonhyperglycemic patients with unadjusted and










All 213 (26.6) 105 (35.5) 0.007
Symptomatic 29 (3.6) 20 (6.8) 0.03 1.87 (1.07–3.25) 1.69 (0.95–3.00)
Outcome at 90 days
Excellent outcome (mRS 0–1) 316 (40) 80 (27.7) 0.001 0.69 (0.56–0.85) 0.7 (0.5–0.9)
Death from all causes (mRS 6) 148 (18.7) 89 (30.8) 0.001 1.64 (1.31–2.06) 1.5 (1.2–1.9)
Data are n (%). Not all percentages are calculated from the total number of patients because certain outcome variables were not available for all patients.
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mRS of 0–1 (Fig. 2C). The predicted
probability of a favorable outcome was
also determined for only those patients
with baseline glucose 8 mmol/l. Even
among these nonhyperglycemic patients,
a linear decline in the probability of a
good outcome was seen with increasing
glucose levels.
CONCLUSIONS — This study fur-
ther conﬁrms the relationship between
admission hyperglycemia and SICH,
death, and poor functional outcome in
ischemic stroke patients treated with IV-
tPA. Our ﬁndings bolster and expand on
those of previous studies, the majority of
whichexaminedsmallernumbersofnon-
thrombolyzed stroke patients and some
of which analyzed hemorrhagic and isch-
emic strokes together (1–3,10).
Published studies of baseline hyper-
glycemia in stroke patients treated with
thrombolysis have been few, were gener-
ally small, and often did not report
3-month outcomes (4,6,12–15). How-
ever, all have suggested an increased risk
of poor outcome with elevated glucose,
despite using different cutoff levels to de-
ﬁne hyperglycemia (from 7.7 to 10
mmol/l)(4,6,12–15).Onestudyincluded
312tPA-treatedpatientsfromtheoriginal
National Institute of Neurological Disor-
ders and Stroke IV-tPA trial and analyzed
these together with 312 placebo-treated
patients (4). This study showed that re-
gardless of treatment assignment, as ad-
mission glucose level increased, the odds
for a favorable outcome progressively de-
creased and the odds of SICH increased
(4). A recent post hoc analysis of 748 pa-
tients from the European Cooperative
Acute Stroke Study (ECASS-II), a trial of
IV-tPA given within6ho fstroke onset,
examined the prognostic value of hyper-
glycemiaatbaselineand24h(6).Patients
were classiﬁed into four groups: isolated
baselinehyperglycemia,isolated24-hhy-
perglycemia, hyperglycemia persisting at
both time points, and persistent normo-
glycemia. Thrombolyzed (n  384) and
nonthrombolyzed (n  364) patients
wereanalyzedtogether.Interestingly,iso-
lated baseline hyperglycemia was not
found to independently predict poor out-
come or ICH. In this study, the strongest
predictor of poor outcome, death, and
ICH was persistent hyperglycemia at
baseline and 24 h, although this observa-
tion was only true in patients without
known diabetes. The prognostic utility of
hyperglycemia exclusively in those pa-
tients treated with IV-tPA cannot be de-
termined because this subgroup was not
analyzed separately. Two other studies of
tPA-treated patients, one with intrave-
nous treatment and the other with intra-
arterial treatment, also showed that
elevatedglucosewasanindependentpre-
dictor of ICH (5,11).
What remains unclear is whether hy-
perglycemiaismerelyanepiphenomenon
of underlying stroke severity or if it is it-
self directly harmful to ischemic brain tis-
sue. After adjustment for clinical stroke
severity, a dose-response relationship be-
tween baseline glucose and unfavorable
outcome is still suggested by our results
and those of others (1,4,6,10). There is
ample animal literature suggesting plau-
sible mechanisms by which glucose may
exert a deleterious effect on ischemic
brain, including cellular acidosis caused
by anaerobic glycolysis, enhanced free
radical production, increased blood-
brain barrier permeability, impaired
mitochondrial function, inﬂux of intra-
cellular Ca
2, and cellular edema (21).
However, noncausal explanations
have also been proposed. Baseline hyper-
glycemia may represent an acute stress
response from activation of the hypotha-
lamic-pituitary-adrenalaxiscausingarise
incortisolandcatecholaminesand,there-
fore, may simply be indicative of under-
lying stroke severity. Furthermore, it may
also be a result of injury or irritation of
brain areas involved in glucose regula-
tion, a theory supported by the associa-
tion of hyperglycemia with strokes
involving the insula (22). Finally, hyper-
glycemia may reﬂect previously undiag-
nosed diabetes.
The argument for causality is also
further mitigated by the equivocal results
of trials targeting aggressive glucose-
lowering therapy in the acute phase after
stroke(8,9).Noevidencetodatesupports
the concept that ensuring strict post-
stroke normoglycemia improves out-
come. The UK Glucose Insulin in Stroke
Trial (GIST-UK) was both stopped early
and underpowered but suggested no dif-
ference in clinical outcome between pa-
Figure 2— A: Probability of SICH by baseline glucose level. Quadratic polynomial line of best ﬁt
with range and 95% CIs adjusted for age, baseline NIHSS score, sex, onset-to-treatment time, and
atrial ﬁbrillation. For each increase of 1 mmol/l of serum glucose, the relative risk of SICH rises
by 10%. B: Probability of death by baseline glucose level. The line and 95% CIs are based upon a
linear regression of predicted probability of death adjusted for age, baseline NIHSS score, sex,
onset-to-treatment time, and baseline ASPECTS score. For every 1 mmol/l rise in the baseline
serum glucose, the probability of death at 90 days increases by an absolute risk of 2%. C: Rela-
tionship between glucose and good outcome. The line and 95% CIs are derived from a fractional
polynomial regression of baseline serum glucose and the predicted probability of good outcome
adjusted for age, baseline NIHSS score, baseline ASPECTS, sex, and onset-to-treatment time. For
every increase of 1 mmol/l of baseline serum glucose, the relative risk of a good outcome falls by
12%.
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potassium-insulin infusion to maintain
glucoselevelsat4–7mmol/lovertheﬁrst
24 h and patients given saline without
glucose-lowering interventions (9). The
lack of beneﬁt may be related to the rela-
tivelylateinitiationoftherapyafterstroke
(median 14 h) and the modest mean re-
duction in glucose achieved in the treat-
ment arm (0.57 mmol/l).
Our prospective cohort study is the
largestyettoreportontheeffectofadmis-
sionglucoseexclusivelyinstrokepatients
treated uniformly with IV-tPA. Our re-
sults conﬁrm the notion that poststroke
hyperglycemia is a predictor of death,
worse functional outcome, and SICH in
thrombolyzed patients. This association
remains true regardless of stroke subtype
or severity and in patients with and with-
out diabetes. We acknowledge that our
work has several limitations. First, it is an
observational study. Nonetheless, the
data were prospectively collected from a
large number of representative patients
drawn from 60 hospitals across Canada.
Second, our results are based on only a
single admission glucose value. Contrary
to data for acute coronary syndromes ar-
guingthatdynamicchangesinglucoseare
not prognostically signiﬁcant (23), it has
recently been suggested that changes in
glucose over the ﬁrst 24 h among stroke
patients may provide additional prognos-
tic value (6). However, use of a single
baselineglucosevaluepresumablyunder-
estimates potential harm, because pa-
tients with the highest admission glucose
levelswouldmostlikelyhavebeentreated
earlier and more aggressively with glu-
cose-lowering therapies. Also, because
thrombolytic treatment is necessarily
rapid,asingleadmissionglucoselevelhas
greater clinical utility for guiding acute
treatment decisions. Third, we did not
collect A1C values and so we do not have
any measures of chronic dysglycemia.
However, in acute coronary syndromes,
A1C levels convey little short-term prog-
nostic value with respect to mortality
(24).Fourth,themethodofbloodglucose
determination was not uniform, with ei-
ther capillary blood or laboratory glucose
measurementsusedatdifferentsites.Both
methods have been shown to provide
comparableresultsincriticallyillpatients
(25). Fifth, we have no information re-
garding glycemic management during
hospitalization or after discharge. Last,
baseline differences between both groups
maybepotentialconfoundersthatcannot
be entirely accounted for using statistical
adjustments.
Although it remains unclear whether
correcting elevated glucose in the acute
phaseafterischemicstrokeisbeneﬁcial,it
isapparentthatadmissionhyperglycemia
rapidly identiﬁes patients at higher risk
forpooroutcomesinwhomglucoselevels
should be closely monitored.
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